All these data indicate that TLR4 may significantly contribute to the pathogenesis of SARS-CoV-2 indicating TLR4 as a promising therapeutic target in COVID-19, which is supported also by the fact that TLR4 antagonists have been previously used in sepsis and in other antiviral contexts [18]. The gene discussed is TLR4; the disease is COVID-19.